Wave Life Sciences Ltd Total Liabilities
Wave Life Sciences Ltd total liabilities. Based on the latest financial reports, Wave Life Sciences Ltd (WVE) has total liabilities worth $71.81 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Wave Life Sciences Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Wave Life Sciences Ltd (2013–2025)
Total liabilities of Wave Life Sciences Ltd from 2013 to 2025. This chart illustrates how Wave Life Sciences Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore WVE long-term investment intensity to see how much of total assets are deployed in long-term investments.
Wave Life Sciences Ltd Competitors by Total Liabilities
The table below lists competitors of Wave Life Sciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shentong Technology Group Co Ltd
SHG:605228
|
China | CN¥754.83 Million |
|
Gujarat Ambuja Exports Limited
NSE:GAEL
|
India | Rs8.65 Billion |
|
Global Top E Commerce Co Ltd
SHE:002640
|
China | CN¥2.45 Billion |
|
Zhejiang Founder Motor Co Ltd
SHE:002196
|
China | CN¥3.32 Billion |
|
Southern California Bancorp
NASDAQ:BCAL
|
USA | $3.44 Billion |
|
First Watch Restaurant Group Inc
NASDAQ:FWRG
|
USA | $1.19 Billion |
|
Zhejiang Dehong Automotive
SHG:603701
|
China | CN¥856.20 Million |
|
SeAH Bestee
KO:001430
|
Korea | ₩2.05 Trillion |
Liability Composition Analysis (2013–2025)
This chart breaks down Wave Life Sciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Wave Life Sciences Ltd total assets.
Liquidity & Leverage Metrics
Wave Life Sciences Ltd Total Liabilities Ratios Explained
Wave Life Sciences Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Wave Life Sciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Wave Life Sciences Ltd (2013–2025)
The table below shows the annual total liabilities of Wave Life Sciences Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $112.27 Million | -21.32% |
| 2024-12-31 | $142.69 Million | -39.36% |
| 2023-12-31 | $235.32 Million | +22.90% |
| 2022-12-31 | $191.48 Million | +9.72% |
| 2021-12-31 | $174.51 Million | -7.46% |
| 2020-12-31 | $188.59 Million | -11.31% |
| 2019-12-31 | $212.64 Million | -4.47% |
| 2018-12-31 | $222.59 Million | +429.62% |
| 2017-12-31 | $42.03 Million | +40.34% |
| 2016-12-31 | $29.95 Million | +150.97% |
| 2015-12-31 | $11.93 Million | +1209.88% |
| 2014-12-31 | $911.00K | -90.97% |
| 2013-12-31 | $10.09 Million | -- |
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more